questionsmedicales.fr
États, signes et symptômes pathologiques
Processus pathologiques
Caractéristiques de la maladie
Maladie chronique
Hépatite chronique
Hépatite chronique : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Hépatite chronique
Biopsie hépatique
Tests sanguins
Enzymes hépatiques
Biopsie hépatique
Inflammation hépatique
Échographie
Anomalies hépatiques
Symptômes
5
Asymptomatique
Hépatite chronique
Prévention
5
Comportements à risque
Drogues
Dépistage
Hépatite chronique
Traitements
5
Antiviraux
Immunomodulateurs
Transplantation hépatique
Insuffisance hépatique
Traitements naturels
Consultation médicale
Suivi médical
Tests sanguins
Complications
5
Insuffisance hépatique
Saignements
Cancer du foie
Hépatite chronique
Facteurs de risque
5
Facteurs de risque
Alcoolisme
Drogues injectables
Hépatite chronique
Antécédents familiaux
Hépatite chronique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hépatite chronique : Questions médicales les plus fréquentes",
"headline": "Hépatite chronique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hépatite chronique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-22",
"dateModified": "2025-02-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hépatite chronique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladie chronique",
"url": "https://questionsmedicales.fr/mesh/D002908",
"about": {
"@type": "MedicalCondition",
"name": "Maladie chronique",
"code": {
"@type": "MedicalCode",
"code": "D002908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hépatite B chronique",
"alternateName": "Hepatitis B, Chronic",
"url": "https://questionsmedicales.fr/mesh/D019694",
"about": {
"@type": "MedicalCondition",
"name": "Hépatite B chronique",
"code": {
"@type": "MedicalCode",
"code": "D019694",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500.477.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hépatite C chronique",
"alternateName": "Hepatitis C, Chronic",
"url": "https://questionsmedicales.fr/mesh/D019698",
"about": {
"@type": "MedicalCondition",
"name": "Hépatite C chronique",
"code": {
"@type": "MedicalCode",
"code": "D019698",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500.477.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hépatite D chronique",
"alternateName": "Hepatitis D, Chronic",
"url": "https://questionsmedicales.fr/mesh/D019701",
"about": {
"@type": "MedicalCondition",
"name": "Hépatite D chronique",
"code": {
"@type": "MedicalCode",
"code": "D019701",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500.477.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hépatite chronique",
"alternateName": "Hepatitis, Chronic",
"code": {
"@type": "MedicalCode",
"code": "D006521",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Heiner Wedemeyer",
"url": "https://questionsmedicales.fr/author/Heiner%20Wedemeyer",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hanover, Hanover, Germany."
}
},
{
"@type": "Person",
"name": "Grace Lai-Hung Wong",
"url": "https://questionsmedicales.fr/author/Grace%20Lai-Hung%20Wong",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China."
}
},
{
"@type": "Person",
"name": "Giuseppina Brancaccio",
"url": "https://questionsmedicales.fr/author/Giuseppina%20Brancaccio",
"affiliation": {
"@type": "Organization",
"name": "Infectious Diseases, Department of Molecular Medicine, University of Padua, Padua, Italy."
}
},
{
"@type": "Person",
"name": "Giovanni B Gaeta",
"url": "https://questionsmedicales.fr/author/Giovanni%20B%20Gaeta",
"affiliation": {
"@type": "Organization",
"name": "Infectious Diseases, Department of Mental and Physical Health, Campania University, Naples, Italy. Electronic address: giovannibattista.gaeta@unicampania.it."
}
},
{
"@type": "Person",
"name": "Maria Buti",
"url": "https://questionsmedicales.fr/author/Maria%20Buti",
"affiliation": {
"@type": "Organization",
"name": "Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Adjuvant Topical Interferon Alpha 2b for the Treatment of Monkeypox Ocular Manifestations.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37643461",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003360"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pegylated Interferon Alpha 2a for the Treatment of Ocular Surface Squamous Neoplasia.",
"datePublished": "2022-07-04",
"url": "https://questionsmedicales.fr/article/36107845",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003086"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interferon-alpha regulates expression of lncRNA MALAT1 and interferon-stimulated genes, as well as chemokine production, in primary Sjögren's syndrome.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36189916",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/ggkc9t"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis.",
"datePublished": "2023-01-26",
"url": "https://questionsmedicales.fr/article/36776844",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1069894"
}
},
{
"@type": "ScholarlyArticle",
"name": "Investigation of an anticancer activity of combination of interferon-alpha and gemcitabine on pancreatic cancer cells.",
"datePublished": "2024-01-22",
"url": "https://questionsmedicales.fr/article/39412913",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/jcrt.jcrt_138_23"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Processus pathologiques",
"item": "https://questionsmedicales.fr/mesh/D010335"
},
{
"@type": "ListItem",
"position": 4,
"name": "Caractéristiques de la maladie",
"item": "https://questionsmedicales.fr/mesh/D020969"
},
{
"@type": "ListItem",
"position": 5,
"name": "Maladie chronique",
"item": "https://questionsmedicales.fr/mesh/D002908"
},
{
"@type": "ListItem",
"position": 6,
"name": "Hépatite chronique",
"item": "https://questionsmedicales.fr/mesh/D006521"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hépatite chronique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hépatite chronique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hépatite chronique",
"description": "Comment diagnostiquer l'hépatite chronique ?\nQuels tests sanguins sont utilisés ?\nQu'est-ce qu'une biopsie hépatique ?\nQuels sont les signes d'hépatite chronique ?\nL'échographie est-elle utile ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Interferon-alpha#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hépatite chronique",
"description": "Quels sont les symptômes courants ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes asymptomatiques ?\nLes démangeaisons sont-elles fréquentes ?\nY a-t-il des symptômes psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Interferon-alpha#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hépatite chronique",
"description": "Comment prévenir l'hépatite chronique ?\nLa vaccination est-elle efficace ?\nQuels comportements à risque éviter ?\nL'hygiène joue-t-elle un rôle ?\nLes tests de dépistage sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Interferon-alpha#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hépatite chronique",
"description": "Quels traitements existent pour l'hépatite chronique ?\nLes antiviraux sont-ils efficaces ?\nQuand faut-il envisager une transplantation ?\nY a-t-il des traitements naturels ?\nComment surveiller l'évolution de la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Interferon-alpha#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hépatite chronique",
"description": "Quelles sont les complications possibles ?\nLa cirrhose est-elle réversible ?\nQuels signes indiquent une insuffisance hépatique ?\nLe cancer du foie est-il fréquent ?\nComment prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Interferon-alpha#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hépatite chronique",
"description": "Quels sont les principaux facteurs de risque ?\nL'usage de drogues augmente-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe sexe influence-t-il le risque ?\nLes voyages à l'étranger sont-ils un risque ?",
"url": "https://questionsmedicales.fr/mesh/D006521?mesh_terms=Interferon-alpha#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hépatite chronique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, des échographies et parfois une biopsie hépatique."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs viraux, les enzymes hépatiques et les tests de fonction hépatique."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une biopsie hépatique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un prélèvement de tissu hépatique pour évaluer l'inflammation et les lésions."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'hépatite chronique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes peuvent inclure fatigue, jaunisse, douleurs abdominales et démangeaisons."
}
},
{
"@type": "Question",
"name": "L'échographie est-elle utile ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'échographie permet de visualiser des anomalies du foie et d'évaluer sa taille."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, jaunisse, douleurs abdominales et perte d'appétit."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse se manifeste par une coloration jaune de la peau et des yeux."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes asymptomatiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent être asymptomatiques malgré une hépatite chronique."
}
},
{
"@type": "Question",
"name": "Les démangeaisons sont-elles fréquentes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les démangeaisons peuvent survenir en raison de l'accumulation de bile dans le sang."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes psychologiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'anxiété et la dépression peuvent être des symptômes associés à l'hépatite chronique."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hépatite chronique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination, l'hygiène et l'évitement des comportements à risque sont essentiels."
}
},
{
"@type": "Question",
"name": "La vaccination est-elle efficace ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vaccination contre l'hépatite A et B est très efficace pour prévenir ces infections."
}
},
{
"@type": "Question",
"name": "Quels comportements à risque éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez le partage d'aiguilles, les rapports sexuels non protégés et l'usage de drogues."
}
},
{
"@type": "Question",
"name": "L'hygiène joue-t-elle un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hygiène personnelle et alimentaire peut réduire le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage régulier est crucial pour détecter l'hépatite chronique tôt."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'hépatite chronique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des antiviraux, des immunomodulateurs et des soins de soutien."
}
},
{
"@type": "Question",
"name": "Les antiviraux sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antiviraux peuvent réduire la charge virale et améliorer la fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quand faut-il envisager une transplantation ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La transplantation est envisagée en cas d'insuffisance hépatique sévère ou de complications graves."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements naturels peuvent aider, mais ils doivent être discutés avec un médecin."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'évolution de la maladie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers avec des tests sanguins et des échographies sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "La cirrhose est-elle réversible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la cirrhose est une condition irréversible, mais son évolution peut être ralentie."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une insuffisance hépatique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, saignements, jaunisse et accumulation de liquide abdominal."
}
},
{
"@type": "Question",
"name": "Le cancer du foie est-il fréquent ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le cancer du foie peut survenir chez les patients atteints d'hépatite chronique."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement approprié peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'infection virale, l'alcoolisme, et certaines maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'usage de drogues augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage de drogues injectables augmente le risque d'hépatite chronique."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hépatite peuvent augmenter le risque de développer la maladie."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains groupes de sexe peuvent avoir un risque plus élevé d'infection virale."
}
},
{
"@type": "Question",
"name": "Les voyages à l'étranger sont-ils un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des régions à forte prévalence d'hépatite peut augmenter le risque d'infection."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 16/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hanover, Hanover, Germany.
Publications dans "Hépatite chronique" :
3 publications dans cette catégorie
Affiliations :
Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Infectious Diseases, Department of Molecular Medicine, University of Padua, Padua, Italy.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Infectious Diseases, Department of Mental and Physical Health, Campania University, Naples, Italy. Electronic address: giovannibattista.gaeta@unicampania.it.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.
Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
National Medical Center for Major Public Health Events, Wuhan, China.
State Key Laboratory for Zoonotic Diseases, Wuhan, China.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
National Medical Center for Major Public Health Events, Wuhan, China.
State Key Laboratory for Zoonotic Diseases, Wuhan, China.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Insitute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea; Liver Center, Severance Hospital, Seoul, South Korea.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Insitute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea; Liver Center, Severance Hospital, Seoul, South Korea.
Publications dans "Hépatite chronique" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Insitute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea; Liver Center, Severance Hospital, Seoul, South Korea.
Publications dans "Hépatite chronique" :
The aim of this study was to report a case of ocular Mpox that responded favorably to treatment with topical interferon and oral doxycycline....
This is a case report of a previously healthy 24-year-old woman who developed a pustular rash, headache, fever, arthralgia, sore throat, and asthenia 3 weeks before attending to our clinic. Her main c...
Mpox with ocular manifestations diagnosis was confirmed by real-time quantitative reverse transcription polymerase chain reaction assay (qRT-PCR) testing; samples were taken from corneal, conjunctival...
Alternative and efficacious treatment options for Mpox ocular manifestations are needed to prevent further disease progression and sequelae in countries with no access to the gold-standard therapy. To...
The purpose of this study was to introduce the initial experience in the use of topical pegylated interferon alpha 2a (PegIFN-α-2a) for ocular surface squamous neoplasia (OSSN)....
A retrospective medical record review of 8 eyes of 8 patients diagnosed with OSSN and treated with PegIFN-α-2a was performed. All cases were diagnosed of noninvasive OSSN both clinically and histologi...
In all 8 cases, topical PegIFN-α-2a was well-tolerated and did not lead to discomfort or any adverse side effects. It resulted in reduction in lesion size and extent in all cases and complete resoluti...
Topical PegIFN-α-2a might be an effective and safe treatment option for noninvasive OSSN....
This study aimed to explore the contribution of interferon-alpha (IFN-α) to MALAT1 expression in primary Sjögren's syndrome (pSS)....
Peripheral blood mononuclear cells (PBMC) from pSS patients and healthy blood donors were stimulated with recombinant human IFN-α, and the expression levels of MALAT1 and several interferon-stimulated...
In this work, we found that MALAT1 expression levels were increased in IFN-α-stimulated PBMC from pSS patients and healthy controls. As expected, ISG expression levels and interferon-regulated chemoki...
Our data provide insights into the abnormal IFN-α-mediated regulation of the lncRNA MALAT1 in pSS. Based on an unusually high capacity of PBMC to express ISG and to produce interferon-responsive chemo...
IFN-α intervention may block SARS-CoV-2 replication and normalize the deregulated innate immunity of COVID-19....
This meta-analysis aimed to investigate the efficacy of interferon IFN-α-containing regimens when treating patients with moderate-to-severe COVID-19....
PubMed, SCOPUS, and ClinicalTrials.gov were searched from inception to 15 January 2022. A systematic literature search was conducted by applying relevant terms for 'COVID-19' and 'interferon-α'. The p...
Eleven studies are enclosed in the meta-analysis. No significant difference in the all-cause mortality rate was found between the study and control groups (OR 0.2; 95% CI 0.05-1.2; I...
Thus, IFN-α does not benefit the survival of hospitalized COVID-19 patients but may increase the number of patients discharged from the hospital....
www.crd.york.ac.uk/prospero, identifier (CRD42022374589)....
Pancreatic ductal adenocarcinoma (PDAC) is still a clinical challenge due to its deteriorated prognosis. Therefore, new combination chemotherapeutic approaches are of research interest. In this work, ...
Surfactants are commonly used in biopharmaceutical formulations to stabilize proteins against aggregation. However, the choice of a suitable surfactant for a particular protein is decided mostly empir...
The addition of interferon to tyrosine kinase inhibitors (TKIs), to improve deep molecular response (DMR) and potentially treatment-free remission (TFR) rates in chronic-phase chronic myeloid leukaemi...
Human interferon alpha 2a (IFNα2a) is a secreted glycoprotein that exerts a wide spectrum of biological effects, such as triggering of antiviral, antitumor and immunosuppressive responses. IFNα2a is u...
The adaptive immune response to viral infections features the antigen-driven expansion of CD8+ T cells. These cells are widely recognized for their cytolytic activity that is mediated through the secr...
Natural killer (NK) cells mount an immune response against hepatitis C virus (HCV) infection and can be activated by several cytokines, including interleukin-2 (IL-2), IL-15, and interferon-alpha (IFN...